1 October 2026 in BJU International
Objectives: To develop and evaluate a complexity‐stratified referral pathway aimed at improving the sustainability, efficiency and resource utilisation of specialist multidisciplinary team (SMDT) meetings within a high‐volume tertiary renal cancer service. Patients and Methods: We performed a retrospective cohort study of benign and malignant renal cancer cases discussed at SMDT meetings between January and December 2023 at the Royal Free Specialist Centre for Kidney Cancer. Patient demographics, tumour characteristics, SMDT discussions and management outcomes of patients were analysed to identify protocolised lower complexity cases suitable for alternative MDT pathways. Based on these findings, dedicated Standard of Care (SoC) and Benign MDTs were developed and implemented to manage lower complexity renal cases outside the main SMDT. The impact of the revised referral structure on SMDT workload, discussion efficiency and specialist resource utilisation was subsequently evaluated. Results: In 2023, 2228 patients with benign and malignant renal pathology underwent 4154 SMDT discussions. Most patients (96.3%) required under seven discussions. Patients aged >70 years with renal masses <2 cm frequently underwent repeated SMDT review, despite surveillance or conservative management representing the most common management recommendation. Bosniak I–II cysts were predominantly discharged, whilst Bosniak IIF cysts were mainly managed with surveillance. Following implementation of the revised referral structure incorporating SoC and Benign MDTs, cases discussed at the main SMDT decreased from a mean of 83 to 63 patients with cancer per week, whilst discussion time per patient increased by 30.8%. The revised pathway also reduced the requirement for full SMDT attendance for protocolised cases. Conclusion: Complexity‐stratified MDT referral structure improved efficiency and sustainability by diverting lower complexity protocolised cases to dedicated Benign and SoC MDTs. This enabled the main SMDT to prioritise clinically complex decision making and optimise utilisation of specialist multidisciplinary expertise.
16 October 2026 in BJUI Compass
Objectives: This study aimed to evaluate decision regret following robot‐assisted laparoscopic partial nephrectomy (RALPN) for benign small renal masses (SRMs) in patients who did not undergo preoperative renal mass biopsy (RMB) and to assess factors associated with regret and satisfaction with treatment decision‐making. Patients and Methods: We conducted a mixed methods study combining retrospective clinical data with prospective patient‐reported outcomes at a high‐volume renal cancer centre. Patients who underwent RALPN for indeterminate SRMs ≤4 cm between January 2010 and July 2025 without preoperative RMB and were subsequently found to have benign histology were identified from a prospectively maintained renal cancer database. Participants completed a standardised questionnaire incorporating the validated Decision Regret Scale (DRS). Significant regret was defined as DRS ≥ 25. Decision regret was evaluated in relation to patients' recollection of counselling and perceived quality of preoperative information. Results: Of 1480 RALPN procedures performed during the study period, 167 patients met the eligibility criteria. Contact was established with 108 patients, of whom 104 agreed to participate and 58 completed the questionnaire. Median age was 66 years, and median tumour size was 30 mm. No Clavien‐Dindo Grade ≥III complications occurred. Most patients recalled being informed that the lesion could be benign (79.3%). Discussion of RMB was recalled by 55.2% of respondents, whereas 29.3% reported no recollection of biopsy discussion. Overall decision regret was low, with a mean DRS of 13.8 (95% confidence interval [CI] 10.3–17.4), although 27.6% demonstrated clinically significant regret (DRS ≥ 25). Despite benign histology, 87.9% believed surgery had been the correct decision and only 29.3% would retrospectively have preferred RMB before surgery. Lower regret scores were observed in patients who recalled detailed RMB discussion and reported higher perceived quality of preoperative counselling. Conclusion: Most patients undergoing RALPN for benign small renal masses reported low decision regret despite ultimately benign pathology. Although over one‐quarter of patients demonstrated clinically significant regret, the majority remained satisfied with their treatment decision and believed surgery had been the correct choice. Comprehensive counselling regarding diagnostic uncertainty and the potential role of renal mass biopsy may help minimise subsequent regret, reinforcing the importance of shared decision‐making in contemporary small renal mass management.